Is Buying Aradigm Corporation (NASDAQ:ARDM), Having Lower Short Interest a Winning Strategy?

September 16, 2018 - By Margaret Downey

Investors sentiment decreased to 0.5 in 2018 Q2. Its down 1.50, from 2 in 2018Q1. It worsened, as 2 investors sold Aradigm Corporation shares while 4 reduced holdings. 1 funds opened positions while 2 raised stakes. 4.08 million shares or 1.11% less from 4.12 million shares in 2018Q1 were reported.
Deutsche Bancorp Ag has invested 0% in Aradigm Corporation (NASDAQ:ARDM). 500 are held by Royal Savings Bank Of Canada. Vanguard Gp has invested 0% in Aradigm Corporation (NASDAQ:ARDM). Geode Capital Ltd accumulated 63,010 shares. Morgan Stanley has 0% invested in Aradigm Corporation (NASDAQ:ARDM). Spark Inv Mngmt Limited Co invested in 28,900 shares. Susquehanna International Grp Incorporated Ltd Liability Partnership reported 33,408 shares or 0% of all its holdings. Fmr Limited Liability invested in 0% or 168,740 shares. Blackrock holds 4,866 shares. First Eagle Inv Management Llc reported 0.01% in Aradigm Corporation (NASDAQ:ARDM). Art Advsr Ltd owns 11,994 shares or 0% of their US portfolio. Northern Trust has invested 0% in Aradigm Corporation (NASDAQ:ARDM).

The stock of Aradigm Corporation (NASDAQ:ARDM) registered a decrease of 24% in short interest. ARDM’s total short interest was 198,900 shares in September as published by FINRA. Its down 24% from 261,700 shares, reported previously. With 19,500 shares average volume, it will take short sellers 10 days to cover their ARDM’s short positions. The short interest to Aradigm Corporation’s float is 2.1%.

The stock decreased 3.10% or $0.04 during the last trading session, reaching $1.25. About 7,330 shares traded. Aradigm Corporation (NASDAQ:ARDM) has declined 3.70% since September 16, 2017 and is downtrending. It has underperformed by 19.32% the S&P500.

Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. The company has market cap of $18.98 million. The companyÂ’s lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq and Lipoquin (ARD-3100) that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis and cystic fibrosis. It currently has negative earnings. It is also developing inhaled ciprofloxacin formulations for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, as well as the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever, and inhaled anthrax.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.